Clinical Trials Browser

Leukemia, Plasma Cell × elotuzumab × Other hematologic neoplasm × Clear all

NCT01729091 2025-05-09

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2 Completed

72 enrolled 14 charts

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma